Nutriband Inc
NTRBW2.680
0.000
Close 06/05, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Nutriband Inc Company
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company Info
Company codeNTRBW
Company nameNutriband Inc
IPO dateJun 20, 2017
Founded at2016
CEOMr. Gareth Sheridan
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address121 S Orange Ave Ste 1500
CityORLANDO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code32801-3241
Phone14073776695
Websitehttps://nutriband.com/
Company codeNTRBW
IPO dateJun 20, 2017
Founded at2016
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sergei Glinka
Mr. Sergei Glinka
Director
Director
--
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
--
--
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
--
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
--
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
--
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sergei Glinka
Mr. Sergei Glinka
Director
Director
--
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
5
140.96K
0.00%
+9.09K
2024Q4
5
140.96K
0.00%
+9.09K
2024Q3
5
131.77K
0.00%
+162.00
2024Q2
6
201.49K
0.00%
-3.06K
2024Q1
6
197.82K
0.00%
+95.55K
2023Q4
5
95.55K
0.00%
-13.13K
2023Q3
5
101.46K
0.00%
+6.05K
2023Q2
5
88.78K
0.00%
+11.98K
2023Q1
4
70.18K
0.00%
-6.46K
2022Q4
2
70.01K
0.00%
-11.97K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
126.39K
0%
+9.80K
+8.41%
Dec 31, 2024
Virtu Americas LLC
10.94K
0%
-211.00
-1.89%
Dec 31, 2024
Clear Street LLC
3.41K
0%
-200.00
-5.54%
Dec 31, 2024
UBS Financial Services, Inc.
215.00
0%
-200.00
-48.19%
Dec 31, 2024
BofA Global Research (US)
--
0%
-100.00
-100.00%
Dec 31, 2023
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
